How to protect yourself when buying GLP-1 online: verify the provider, the pharmacy, the prescription basis, and the regulatory status.
• Confirm a real provider evaluation and a documented prescription basis.
• Ask which pharmacy fills it (503A/503B) and whether it’s accredited.
• Confirm whether the product is compounded or FDA-approved.
• Read cancellation/refund terms before prepaying.
• Be wary of “generic,” “same as branded,” “FDA-approved pharmacy,” and pressure tactics.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.